Biotech Values

[Summer2762]

So if the HR for those two subgroups is <0.5 and there are 100 patients enrolled then as long as the 15-30 pct remainder isn't hurt it might well be stat sig.

If that were the case, they would not have changed the primary end point the trial. Thus, as a logical inference, a) either the p value of the two subpopulations is ~0.05 so that 15-30 pct remainder make a difference or b) the % of patients in these two subpopulations is not large (say < 50%). This inference, of course, depends on the assumption that the co wants to pr that the P2 portion of the GALAXY trial met its primary endpoint and that's why they changed the primary end point of the trial.